Deferoxamine for the treatment of hemosiderosis during CAPD.
The effects of chelation therapy by intravenous and intraperitoneal administration of deferoxamine were compared during maintenance continuous ambulatory peritoneal dialysis (CAPD) in a child with end stage renal disease and hemosiderosis. We demonstrate that intraperitoneally administered deferoxamine is safer, more practical and efficient than weekly intravenously administered deferoxamine for the treatment of iron overload in the pediatric patient undergoing CAPD.
D000293:Adolescent; D003676:Deferoxamine / Q000627:therapeutic use*; D005260:Female; D006486:Hemosiderosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*
D003676:Deferoxamine